Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1137357

Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection


Perkovic, Nikola; Mestrovic, Antonio; Bozic, Josko; Pavicic Ivelja, Mirela; Vukovic, Jonatan; Kardum, Goran; Sundov, Zeljko; Tonkic, Marija; Puljiz, Zeljko; Vukojevic, Katarina; Tonkic, Ante
Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection // Journal of personalized medicine, 11 (2021), 6; 11060534, 10 doi:https://.org/10.3390/jpm11060534 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1137357 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection

Autori
Perkovic, Nikola ; Mestrovic, Antonio ; Bozic, Josko ; Pavicic Ivelja, Mirela ; Vukovic, Jonatan ; Kardum, Goran ; Sundov, Zeljko ; Tonkic, Marija ; Puljiz, Zeljko ; Vukojevic, Katarina ; Tonkic, Ante

Izvornik
Journal of personalized medicine (2075-4426) 11 (2021), 6; 11060534, 10

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
H. pylori ; concomitant therapy ; tailored therapy ; gastritis ; antimicrobial resistance

Sažetak
As high clarithromycin resistance (>20%) in the Split-Dalmatia region of Croatia hinders the treatment of H. pylori infection, the primary objective of this study was to compare concomitant quadruple with the tailored, personalized therapy as first-line eradication treatment of H. pylori. In an open-label, randomized clinical trial, 80 patients with H. pylori infection were randomly assigned to either concomitant (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days) or tailored therapy in accordance with the results of the antimicrobial susceptibility testing. Eradication status was assessed 4 weeks after treatment. Eradication rates were significantly higher in tailored group than in concomitant group both in intention-to- treat (70 vs. 92.5%, p = 0.010) and per-protocol (87.5 vs. 100%, p = 0.030) analysis in the setting of increasing antibiotic resistance (clarithromycin 37.5%, metronidazole 17.5%, dual resistance 10%). Adverse effects were more frequent in the concomitant group (32.5 vs. 7.5%, p = 0.006). Tailored therapy achieves higher eradication with a lower adverse events rate. With the increasing resistance of H. pylori strains to antibiotic treatment, eradication regimes with such characteristics should be strongly considered as a reasonable choice for first- line treatment.

Izvorni jezik
Engleski

Poveznice na cjeloviti tekst rada:

doi

Citiraj ovu publikaciju:

Perkovic, Nikola; Mestrovic, Antonio; Bozic, Josko; Pavicic Ivelja, Mirela; Vukovic, Jonatan; Kardum, Goran; Sundov, Zeljko; Tonkic, Marija; Puljiz, Zeljko; Vukojevic, Katarina; Tonkic, Ante
Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection // Journal of personalized medicine, 11 (2021), 6; 11060534, 10 doi:https://.org/10.3390/jpm11060534 (međunarodna recenzija, članak, znanstveni)
Perkovic, N., Mestrovic, A., Bozic, J., Pavicic Ivelja, M., Vukovic, J., Kardum, G., Sundov, Z., Tonkic, M., Puljiz, Z., Vukojevic, K. & Tonkic, A. (2021) Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. Journal of personalized medicine, 11 (6), 11060534, 10 doi:https://.org/10.3390/jpm11060534.
@article{article, author = {Perkovic, Nikola and Mestrovic, Antonio and Bozic, Josko and Pavicic Ivelja, Mirela and Vukovic, Jonatan and Kardum, Goran and Sundov, Zeljko and Tonkic, Marija and Puljiz, Zeljko and Vukojevic, Katarina and Tonkic, Ante}, year = {2021}, pages = {10}, DOI = {https://doi.org/10.3390/jpm11060534}, chapter = {11060534}, keywords = {H. pylori, concomitant therapy, tailored therapy, gastritis, antimicrobial resistance}, journal = {Journal of personalized medicine}, doi = {https://doi.org/10.3390/jpm11060534}, volume = {11}, number = {6}, issn = {2075-4426}, title = {Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection}, keyword = {H. pylori, concomitant therapy, tailored therapy, gastritis, antimicrobial resistance}, chapternumber = {11060534} }
@article{article, author = {Perkovic, Nikola and Mestrovic, Antonio and Bozic, Josko and Pavicic Ivelja, Mirela and Vukovic, Jonatan and Kardum, Goran and Sundov, Zeljko and Tonkic, Marija and Puljiz, Zeljko and Vukojevic, Katarina and Tonkic, Ante}, year = {2021}, pages = {10}, DOI = {https://doi.org/10.3390/jpm11060534}, chapter = {11060534}, keywords = {H. pylori, concomitant therapy, tailored therapy, gastritis, antimicrobial resistance}, journal = {Journal of personalized medicine}, doi = {https://doi.org/10.3390/jpm11060534}, volume = {11}, number = {6}, issn = {2075-4426}, title = {Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection}, keyword = {H. pylori, concomitant therapy, tailored therapy, gastritis, antimicrobial resistance}, chapternumber = {11060534} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font